WO2012030738A3 - Complex phosphoprotein activation profiles - Google Patents

Complex phosphoprotein activation profiles Download PDF

Info

Publication number
WO2012030738A3
WO2012030738A3 PCT/US2011/049596 US2011049596W WO2012030738A3 WO 2012030738 A3 WO2012030738 A3 WO 2012030738A3 US 2011049596 W US2011049596 W US 2011049596W WO 2012030738 A3 WO2012030738 A3 WO 2012030738A3
Authority
WO
WIPO (PCT)
Prior art keywords
complex
phosphoprotein
methods
activation
activation profiles
Prior art date
Application number
PCT/US2011/049596
Other languages
French (fr)
Other versions
WO2012030738A2 (en
Inventor
James Jacobberger
Charles Goolsby
David Hedley
Vincent Shankey
Philip Woost
Sue Chow
James Marvin
Original Assignee
Beckman Coulter, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckman Coulter, Inc. filed Critical Beckman Coulter, Inc.
Publication of WO2012030738A2 publication Critical patent/WO2012030738A2/en
Publication of WO2012030738A3 publication Critical patent/WO2012030738A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present specification discloses methods for determining a phosphoprotein activation profile in hematopoietic cells, methods for detecting a signal transduction activation state in an individual having or suspected of having a disease or condition associated with activation of a signal transduction pathway, methods for detecting leukemia, and kits for determining a phosphoprotein activation profile in a sample containing hematopoietic cells.
PCT/US2011/049596 2010-08-30 2011-08-29 Complex phosphoprotein activation profiles WO2012030738A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37824610P 2010-08-30 2010-08-30
US37825810P 2010-08-30 2010-08-30
US61/378,258 2010-08-30
US61/378,246 2010-08-30

Publications (2)

Publication Number Publication Date
WO2012030738A2 WO2012030738A2 (en) 2012-03-08
WO2012030738A3 true WO2012030738A3 (en) 2012-04-26

Family

ID=44645213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/049596 WO2012030738A2 (en) 2010-08-30 2011-08-29 Complex phosphoprotein activation profiles

Country Status (1)

Country Link
WO (1) WO2012030738A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9885708B2 (en) * 2012-11-27 2018-02-06 Deepath Medical Inc. Methods and combinations of signaling markers for assessment of disease states
ES2928773T3 (en) 2017-01-17 2022-11-22 Heparegenix Gmbh Protein kinase inhibitors to promote liver regeneration or reduce or prevent hepatocyte death

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031545A2 (en) * 1994-05-13 1995-11-23 Children's Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated crkl protein
WO2008009004A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2010028277A1 (en) * 2008-09-04 2010-03-11 Beckman Coulter, Inc. Pan-kinase activation and evaluation of signaling pathways

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (en) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
WO1992015673A1 (en) 1991-03-11 1992-09-17 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
ATE199392T1 (en) 1992-12-04 2001-03-15 Medical Res Council MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE
ATE400651T1 (en) 1993-09-10 2008-07-15 Univ Columbia USE OF GREEN FLUORESCENT PROTEIN
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2271717A1 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
DE69938293T2 (en) 1998-03-27 2009-03-12 Bruce J. Beverly Hills Bryan LUCIFERASE, GFP FLUORESCENCE PROTEINS, CODING NUCLEIC CAUSE, AND ITS USE IN DIAGNOSIS
IL149171A0 (en) 1999-11-16 2002-11-10 Genentech Inc Elisa for vegf
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031545A2 (en) * 1994-05-13 1995-11-23 Children's Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated crkl protein
WO2008009004A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2010028277A1 (en) * 2008-09-04 2010-03-11 Beckman Coulter, Inc. Pan-kinase activation and evaluation of signaling pathways

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Cytometry", 1 October 2008, JOHN WILEY & SONS, INC., Hoboken, NJ, USA, ISBN: 978-0-47-114295-9, article CHOW S ET AL.: "Whole Blood Processing for Measurement of Signaling Proteins by Flow Cytometry", XP055006222 *
CHOW S ET AL: "Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 34, no. 9, 1 September 2006 (2006-09-01), pages 1182 - 1190, XP025017542, ISSN: 0301-472X, [retrieved on 20060901], DOI: 10.1016/J.EXPHEM.2006.05.002 *
MARVIN J ET AL: "Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML", BLOOD, vol. 117, no. 15, 13 January 2011 (2011-01-13), pages E120 - E130, XP002663831 *
WOOST PG ET AL: "High-resolution kinetics of cytokine signalinh in human CD34/CD117-positive cells in unfractionated bone marrow", BLOOD, vol. 117, no. 15, 17 February 2011 (2011-02-17), pages E131 - E141, XP002663832 *

Also Published As

Publication number Publication date
WO2012030738A2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
WO2009129505A3 (en) Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
MX2020004617A (en) Cardiovascular risk event prediction and uses thereof.
WO2013134503A3 (en) Methods And Compositions For Detecting Multiple Analytes With A Single Signal
WO2011150115A3 (en) Methods and apparatus for point-of-care detection of nucleic acid in a sample
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
WO2014058760A3 (en) Preloaded test substrates for testing lal-reactive substances, methods of use, and methods of making
WO2010039809A3 (en) Primers and probes for detecting human papillomavirus and human beta globin sequences in test samples
MY170983A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
WO2012120288A3 (en) Method, array and use for determining the presence of pancreatic cancer.
WO2013062515A3 (en) Lung cancer biomarkers and uses thereof
WO2010088668A3 (en) Methods of detecting sepsis
WO2012033537A8 (en) Benchmarks for normal cell identification
WO2013083781A3 (en) Biomarkers and test panels useful in systemic inflammatory conditions
WO2014083427A3 (en) Compositions and methods for detecting vitamin d
WO2012096545A3 (en) Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof
WO2011085163A3 (en) Protein markers for lung cancer detection and methods of using thereof
WO2012074972A3 (en) Non-destructive testing methods for fuel cell interconnect manufacturing
WO2008106648A3 (en) Immunoassays exhibiting a reduction in prozone phenomena
BRPI1013896A2 (en) Yeast cell, and methods for producing an isoprenoid compound and for detecting in a biological sample the presence or absence of a genetically microbial cell.
WO2012170206A3 (en) Color-producing diagnostic systems, reagents and methods
WO2007106507A3 (en) Detection of gene expression in mixed sample or tissue
WO2012032345A3 (en) Biomarker signatures and uses thereof
WO2013028807A3 (en) Renal cell carcinoma biomarkers and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11755187

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11755187

Country of ref document: EP

Kind code of ref document: A2